{"id":56,"date":"2013-02-21T21:51:59","date_gmt":"2013-02-21T21:51:59","guid":{"rendered":"https:\/\/previewbreastscreening.com\/?page_id=56"},"modified":"2018-09-28T08:30:02","modified_gmt":"2018-09-28T12:30:02","slug":"56-2","status":"publish","type":"page","link":"https:\/\/previewbreastscreening.com\/?page_id=56","title":{"rendered":"For Professionals"},"content":{"rendered":"

Personalized\u00a0Breast Cancer Screening\u00a0For Better Detection\u00a0in Dense Breast Tissue<\/b><\/span><\/p>\n

3D Automated breast ultrasound ( ABUS<\/b>TM)<\/sup><\/b>\u00a0is the latest technological advancement in breast ultrasound imaging\u00a0from GE Healthcare, specifically designed to address the functional limitations of screening mammography for women\u00a0with dense breast tissue affecting\u00a0over 40% of\u00a0women considered to be at a 4-6 times higher risk for breast cancer. \u00a0It’s the only FDA and Health Canada approved ultrasound breast cancer screening device indicated for enhanced surveillance as an adjunct\u00a0to mammography,\u00a0particularly for ongoing mammographic breast density cases of normal or benign findings. \u00a0Screening ABUS has been shown to offer clinicians and their patients a life-saving opportunity for\u00a0the detection of\u00a0previously undetectable and suspicious\u00a0cancers\u00a0in dense tissue\u00a0that are potentially smaller, less invasive, node negative, and\u00a0at an earlier more treatable stage requiring less invasive protocols.<\/p>\n

ABUS Delivers Exceptional 3D Image\u00a0Quality for\u00a0<\/b>Complete<\/b>\u00a0Breast Mapping and Accurate Interval Comparison<\/b><\/span><\/p>\n

ABUS\u00a0delivers exceptional 3D image quality using a large,\u00a0automated<\/i>\u00a0scanning probe that virtually eliminates operator skill variability and completely maps and triangulates the\u00a0entire\u00a0breast area for accurate interval comparison between studies, helping to deliver greater clarity and peace of mind to both patients and healthcare providers. \u00a0The ABUS\u00a0scanning probe is gently positioned at\u00a0three different\u00a0locations on each breast by a licensed and ABUS-certified\u00a0sonographer, allowing for the acquisition of approximately three hundred image slices per scan, totaling 900 image slices per breast, from the skin’s surface back to the chest wall. In just minutes, 3D-reconstructed images are rendered using proprietary software,\u00a0capturing\u00a0precise\u00a0anatomical detail of complex breast tissues and structures\u00a0to be reviewed by the radiologist who\u00a0can virtually peel back the layers (or image slices) of breast tissue to visualize suspicious abnormalities which may be hidden by dense tissue on a mammogram. Although the sensitivity, specificity and reproducibility of ABUS is proven to be high, it’s accuracy\u00a0is\u00a0optimized by the reading radiologist who is trained and experienced in the interpretation of ABUS images.<\/p>\n

The complete field of view covers 15cm x 17cm x 5.0cm. The machine has both a high center-frequency enabling high resolution and ultra broadband characteristics for optimal contrast.\u00a0The standard quality and utility of\u00a0ABUS\u00a0is exponentially better than handheld\u00a0ultrasound\u00a0which is\u00a0limited by\u00a0operator-skill variability, and limitations in\u00a0acquiring\u00a0triangulated reference data of the entire breast area for accurate interval comparison. \u00a0For these reasons handheld is primarily indicated as a valuable\u00a0followup diagnostic imaging tool for spot-checking suspicious areas of concern identified in\u00a0a\u00a0screening mammogram or ABUS.<\/p>\n

Helping Clinicians Look Differently at Dense Breast Tissue One ABUS Scan at a Time –\u00a0<\/b>Mammogram Alone Is Not Enough<\/b><\/span><\/p>\n

Clinicians are\u00a0now incorporating ABUS\u00a0as part of a more personalized and preventative screening\u00a0strategy for their patients to help find the up to 50% of cancers that mammography potentially misses in dense breasts. Multiple studies have shown that 91% of ABUS-detected cancers were confirmed as invasive, smaller, non-negative and more treatable in various asymptomatic screening populations with higher breast density when used to augment normal or benign mammograms.<\/p>\n

ABUS is Not just for Women with Dense Breasts<\/b><\/span><\/p>\n

ABUS is also recommended\u00a0by many prevention-focused clinicians\u00a0for general breast cancer screening with an interest in acquiring earlier baseline and comparative information\u00a0for a timely understanding of subtle\u00a0tissue changes that can be monitored and proactively addressed as needed, well\u00a0before breast cancer develops.\u00a0As\u00a0supplementary screening\u00a0information\u00a0is\u00a0acquired\u00a0at an earlier stage\u00a0using\u00a0ABUS, patients become\u00a0much more engaged and\u00a0comfortable\u00a0about their own breast health\u00a0as\u00a0part of an ongoing\u00a0learning process\u00a0which\u00a0leads\u00a0to better\u00a0decision-making, more available and less aggressive treatments, and healthier outcomes.<\/p>\n

All women at every stage of\u00a0life are taking advantage of ABUS regardless of their medical history, including younger, pregnant and lactating women, or other individuals at higher risk\u00a0(ie. hormone therapy, surgical history [augmentation, reduction,\u00a0biopsy, lumpectomy, mastectomy, or reconstruction] who don’t easily qualify for\u00a0OHIP-covered methods but prefer earlier and proactive baseline screening and monitoring. \u00a0Many patients with dense tissue whose annual or bi-annual mammograms\u00a0have been consistently normal or benign, are introducing\u00a0ABUS more frequently into their regular screening protocol\u00a0for its added value\u00a0and to\u00a0help minimize\u00a0their cumulative radiation\u00a0risks\u00a0and tissue discomfort and stress from the heavy compression of mammography.<\/p>\n

ABUS Meets Quality Assurance Standards to Protect Patient Care<\/b><\/span><\/p>\n

ABUS is\u00a0not\u00a0currently covered under OHIP\u00a0as part of the Ontario breast screening program (OBSP), however it is currently accessible at the PreView Breast Screening clinic in Barrie whose\u00a0licensed sonographers, radiologists and support staff, work responsibility to comply with\u00a0the clinical practice parameters and imaging standards of\u00a0the Ministry of Health and Long-Term Care for independent health facilities, and with the breast ultrasound examination and teleradiology standards of\u00a0the Canadian Association of Radiologists.<\/p>\n

Clinicians Must Fulfill their Leadership Role in the Breast Screening Process<\/b><\/span><\/p>\n

Through better access to research, healthcare professionals are becoming much more\u00a0informed about breast density, the limitations of screening mammography, and the evidence-based advantages of\u00a0ABUS as a valuable adjunctive screening tool. \u00a0Consequently, a growing\u00a0number of clinicians and their patients are advocating\u00a0for\u00a0breast density reporting and notification from their mammogram reports and screening supplementation with\u00a0ABUS. As patients become better informed about their breast health,\u00a0healthcare providers\u00a0are obligated to meet each patient’s own unique breast health needs and to minimize their risk factors based on\u00a0reliable data from a more proactive and personalized\u00a0breast screening program\u00a0including mammography, adjunctive ABUS, clinical\/self breast examinations and supporting lab data. As with\u00a033 out of 50 states in the USA, provincial health ministries in Canada are finally beginning to follow suit, starting with the province of BC which legislated breast density reporting and notification in October 2018.<\/p>\n

\"breast<\/p>\n

\"breast<\/p>\n

Considered\u00a0the largest trial ever undertaken by an ultrasound company, the SOMO\u2212INSIGHT was\u00a0a multi-center nationwide clinical research study in the US, sponsored by U-Systems who worked with some of North America’s leading breast imaging experts to\u00a0evaluate the ability of somo-v ABUS to improve cancer detection rates for women with greater than fifty percent dense breast tissue. Up to 20,000 patients were enrolled in the study which resulted in a\u00a0significant number of mammographically negative breast cancers that would not have otherwise been detected had the participants not had an ABUS exam.<\/p>\n

\"breast<\/p>\n

The EASY Clinical Study (European Asymptomatic Screening Study) is a large European clinical research study sponsored by U-Systems Inc. to evaluate the integration of ABUS into the routine practices of a high-volume hospital-based breast cancer screening program in Stockholm, Sweden. The clinical study was designed to determine whether Full Field Digital Mammography combined with ABUS could improve breast cancer detection when compared to mammography alone in women with dense breast tissue.<\/p>\n

The study protocol accommodated the standard screening practices in Sweden and outlined a process for integrating ABUS review into an existing double-reading system where two different radiologists independently reviewed breast image exams.<\/p>\n

The EASY study recruited 8,000 asymptomatic women with dense breast tissue and although the results of the primary analysis were\u00a0not intended to reach statistical significance, they yielded valuable trending information about the potential impact on existing cancer detection rates of a multi-modality approach combining ABUS with routine mammography to improve the\u00a0accuracy of routine screenings for women with dense breast tissue.<\/p>\n

\"breast<\/p>\n

Click\u00a0here<\/b><\/a>\u00a0for mammographic breast density and 3D Automated Breast Ultrasound (ABUS)\u00a0research and general interest articles<\/span><\/b>.<\/span><\/p>","protected":false},"excerpt":{"rendered":"

Personalized\u00a0Breast Cancer Screening\u00a0For Better Detection\u00a0in Dense Breast Tissue 3D Automated breast ultrasound ( ABUSTM)\u00a0is the latest technological advancement in breast ultrasound imaging\u00a0from GE Healthcare, specifically designed to address the functional limitations of screening mammography for women\u00a0with dense breast tissue affecting\u00a0over 40% of\u00a0women considered to be at a 4-6 times higher risk for breast cancer. \u00a0It’s […]<\/p>\n","protected":false},"author":100000,"featured_media":242,"parent":9,"menu_order":4,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-56","page","type-page","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/previewbreastscreening.com\/index.php?rest_route=\/wp\/v2\/pages\/56","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/previewbreastscreening.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/previewbreastscreening.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/previewbreastscreening.com\/index.php?rest_route=\/wp\/v2\/users\/100000"}],"replies":[{"embeddable":true,"href":"https:\/\/previewbreastscreening.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56"}],"version-history":[{"count":116,"href":"https:\/\/previewbreastscreening.com\/index.php?rest_route=\/wp\/v2\/pages\/56\/revisions"}],"predecessor-version":[{"id":1023,"href":"https:\/\/previewbreastscreening.com\/index.php?rest_route=\/wp\/v2\/pages\/56\/revisions\/1023"}],"up":[{"embeddable":true,"href":"https:\/\/previewbreastscreening.com\/index.php?rest_route=\/wp\/v2\/pages\/9"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/previewbreastscreening.com\/index.php?rest_route=\/wp\/v2\/media\/242"}],"wp:attachment":[{"href":"https:\/\/previewbreastscreening.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}